Second infliximab biosimilar coming soon

The makers of the second biosimilar to infliximab renflexis say they intend to  launch the drug in Australia in the second half of this year. The PBAC approved the biosimilar marketed by MSD and Samsung Bioepis earlier this year on a cost minimisation basis with infliximab (Remicade) for all indications – rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ...

Already a member?

Login to keep reading.

© 2021 the limbic